Humanized anti-complement factor Bb antibodies

Patent metadata

Field	Value
Publication number	US-11242382-B2
Application number	US-202117234618-A
Country	US
Kind code	B2
Filing date	Apr 19, 2021
Priority date	Apr 20, 2020
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.

First claim

What is claimed is:

1. A humanized antibody that binds specifically to human complement factor Bb protein, wherein the antibody comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable region (V L ) comprising the amino acid sequence of SEQ ID NO: 27.

2. The humanized antibody of claim 1 , wherein the humanized antibody is a multispecific antibody.

3. The humanized antibody of claim 2 , wherein the multispecific antibody is a bispecific antibody.

4. The humanized antibody of claim 1 , wherein the humanized antibody is selected from the group consisting of an Ig monomer, a Fab fragment, a F(ab′) 2 fragment, a scFv, a scAb, and a Fv.

5. The humanized antibody of claim 1 , wherein the humanized antibody comprises a heavy chain constant region of the isotype IgG1, IgG2, IgG3, or IgG4.

6. The humanized antibody of claim 5 , wherein the humanized antibody comprises an IgG4 constant region.

7. The humanized antibody of claim 6 , wherein the IgG4 constant region comprises an S241P substitution and an L248E substitution, by Kabat numbering.

8. The humanized antibody of claim 7 , wherein the IgG4 constant region further comprises an M459L substitution and an N466S substitution, by Kabat numbering.

9. The humanized antibody of claim 1 , wherein the humanized antibody comprises a heavy chain constant region comprising the amino acid sequence of any one of SEQ Nos. 28-30.

10. The humanized antibody of claim 1 , wherein the humanized antibody comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 31.

11. The humanized antibody of claim 9 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 32 and a light chain comprising the amino acid sequence of SEQ. ID NO: 35.

12. The humanized antibody of claim 9 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 33 and a light chain comprising the amino acid sequence of SEQ ID NO: 35.

13. The humanized antibody of claim 9 , wherein the humanized antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 34 and a light chain comprising the amino acid sequence of SEQ ID NO: 35.

14. A conjugate comprising the humanized antibody of claim 1 .

15. The conjugate of claim 14 , wherein the humanized antibody is conjugated to a therapeutic agent.

16. A composition comprising the humanized antibody of claim 1 .

17. The composition of claim 16 , further comprising a pharmaceutically acceptable excipient.

Assignees

• Genzyme Corp

Inventors

• Parry Graham
• Moore Stephen
• Storek Michael
• Leksa Nina C

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/31

  multispecific · CPC title